Skip to main content

Table 2 Summary statistics of GC doses and duration of use per patient during follow-up and in the 12 months prior to study entry for those patients ever prescribed GCs (n = 7777)

From: Half of UK patients with rheumatoid arthritis are prescribed oral glucocorticoid therapy in primary care: a retrospective drug utilisation study

  Follow-up period 12 months prior to study entry
Measure* Median IQR Median IQR
Duration of follow-up (years) 5.29 2.62–8.58 - -
Cumulative duration of GC use (years) 0.80 0.15–2.56 0.23 0.05–0.67
Proportion of follow-up time on GCs (%) 26.3 3.8–70.0 22.7 5.4–67.2
Average dose** (mg) 7.5 5–15.3 10 5–20
Lowest dose** (mg) 5 2.5–7.5 5 3–15
Highest dose** (mg) 15 7.5–30 15 6–30
  1. GC glucocorticoid, IQR interquartile range
  2. *Summary statistics were obtained by calculating the value for each patient and then determining median values across the whole population
  3. **All doses are prednisolone-equivalent daily doses